Skip to content

Clinical Study on Integrated Prevention and Treatment of Gouty Arthritis by Integrative Chinese and Western Medicine

Clinical Study on Integrated Prevention and Treatment of Gouty Arthritis by Integrative Chinese and Western Medicine

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-16009496
Enrollment
Unknown
Registered
2016-10-19
Start date
2017-04-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gouty arthritis

Interventions

Acute phase group 1:Huzhang Gout Granule
Acute phase group 2:Nimesulide dispersible tablets
Acute phase group 3:Huzhang Gout Granule+Nimesulide dispersible tablets
Remission period group 1:Yinlian Gout Granule
Remission period group 2:Benzbromarone tablets
Remission period group 3:Yinlian Gout Granule+Benzbromarone tablets

Sponsors

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine .Shanghai Unversity of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Signed a informed consent and dated; 2. Male and femael aged 18~75 years; 3. Accord to the above criteria for diagnosis of gouty arthritis and traditional Chinese medicine syndrome differentiation standards; 4. The cause of gouty arthritis is longer than 1 year. Gouty arthritis attacks more than four times a year; 5. the standard of the acute phase is the pain Within the scope of 48 hours and Within one week before the period of the observation not taking anti-inflammatory analgesic and other non-steroidal anti-inflammatory drugs and drugs affect the uric acid metabolism; 6. Agreed to participate in the clinic trials and cooperate with follow-up on schedule.

Exclusion criteria

Exclusion criteria: 1. Does not meet the inclusion criteria; 2. Combined with cardiovascular and cerebrovascular, liver, kidney and hematopoietic system and other serious primary disease, renal insufficiency, kidney stones and mental patients; 3. Patients with active gastrointestinal disease, and patients with gastrointestinal ulcers within the first 30 days of the study; 4. Allergic to the medicine used in the trial.

Design outcomes

Primary

MeasureTime frame
Laboratory examination;Safety indicators;Numeric pain rating scale(NRS-11);TCM symptoms integral;

Countries

China

Contacts

Public ContactMing Zhang

Department of Dematology, Yueyang Hospital Affiliated to Shanghai University of TCM

drzhangming_sh@163.com+86 021-65164621

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026